Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00160472 · ClinicalTrials.gov registry record · NA
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms
A NA study, sponsored by United States Department of Defense.
- Completed
- Registry status
- NA
- Development phase
- 110
- Enrollment target
NCT00160472 is a NA study that has completed, run by United States Department of Defense. The registered enrollment target is 110 participants.
The verdict
NCT00160472, a NA study, has completed, sponsored by United States Department of Defense.
- COMPLETED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
Study Summary
This study will evaluate the expression of arginine vasopressin (AVP) by peptide and mRNA quantitation and also measurement of its V1 receptor mRNA, in the arteries and veins of ovarian malignant (cancerous) or benign (non-cancerous) tissue. The investigators will examine whether AVP protein and AVP and V1 receptor mRNA expression vary with respect to tumor histology, intratumoral vascularization and systemic blood pressure.
Interventions
- PROCEDURE removal of ovarian vessels
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2004-03 |
| Est. Completion | 2009-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00160472
The ClinicalTrials.gov registry entry for NCT00160472 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United States Department of Defense, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which removal of ovarian vessels is the first listed.
NCT00160472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00160472 about?
NCT00160472 is a clinical study titled "Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms". This study will evaluate the expression of arginine vasopressin (AVP) by peptide and mRNA quantitation and also measurement of its V1 receptor mRNA, in the arteries and veins of ovarian malignant (cancerous) or benign (non-cancerous) tissue. The investigators will examine whether AVP protein and AVP...
What is the current status of trial NCT00160472?
This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2004-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00160472?
The interventions under investigation include: removal of ovarian vessels (PROCEDURE).
Who is sponsoring clinical trial NCT00160472?
This trial is sponsored by United States Department of Defense, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.